• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Idiopathic Anaphylaxis.特发性过敏反应
Curr Treat Options Allergy. 2017;4(3):312-319. doi: 10.1007/s40521-017-0136-2. Epub 2017 Jun 3.
2
Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).膜翅目昆虫毒液过敏的诊断与治疗:德国变态反应与临床免疫学会(DGAKI)与职业与环境皮肤病学会(ABD)、德国变态反应科医生协会(AeDA)、德国皮肤病学会(DDG)、德国耳鼻咽喉头颈外科学会(DGHNOKC)、德国儿科学与青少年医学学会(DGKJ)、儿童变态反应与环境医学学会(GPA)、德国呼吸学会(DGP)以及奥地利变态反应与免疫学会(ÖGAI)联合发布的S2k指南
Allergol Select. 2023 Oct 2;7:154-190. doi: 10.5414/ALX02430E. eCollection 2023.
3
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
4
Anaphylaxis: Recognition and Management.过敏反应:识别与管理。
Am Fam Physician. 2020 Sep 15;102(6):355-362.
5
Anaphylaxis.过敏反应
J Med Assoc Thai. 2007 Jan;90(1):195-200.
6
How to manage anaphylaxis in primary care.基层医疗中如何管理过敏反应。
Clin Transl Allergy. 2017 Dec 11;7:45. doi: 10.1186/s13601-017-0182-7. eCollection 2017.
7
Bugged.有故障的;有缺陷的
Emerg Med Serv. 2003 May;32(5):48.
8
Idiopathic anaphylaxis.特发性过敏反应。
Clin Exp Allergy. 2019 Jul;49(7):942-952. doi: 10.1111/cea.13402. Epub 2019 May 13.
9
[Treatment of anaphylactic shock].[过敏性休克的治疗]
Ther Umsch. 2001 May;58(5):325-8. doi: 10.1024/0040-5930.58.5.325.
10
International consensus on (ICON) anaphylaxis.国际过敏共识(ICON):过敏反应。
World Allergy Organ J. 2014 May 30;7(1):9. doi: 10.1186/1939-4551-7-9. eCollection 2014.

引用本文的文献

1
Level of Awareness of Certified Non-critical Care Physicians in Diagnosing, Managing, and Disposing Anaphylactic Cases.认证非重症监护医师对过敏性病例的诊断、管理和处置的意识水平。
Med Arch. 2024;78(1):44-50. doi: 10.5455/medarh.2024.78.44-50.
2
sCD14 and Intestinal Fatty Acid Binding Protein Are Elevated in the Serum of Patients With Idiopathic Anaphylaxis.特发性过敏症患者血清中 sCD14 和肠脂肪酸结合蛋白水平升高。
J Allergy Clin Immunol Pract. 2023 Jul;11(7):2080-2086.e5. doi: 10.1016/j.jaip.2023.03.037. Epub 2023 Mar 29.
3
Anaphylaxis in Children and Adolescents: Greek Data Analysis from the European Anaphylaxis Registry (NORA).儿童和青少年过敏反应:来自欧洲过敏反应登记处(NORA)的希腊数据分析
J Pers Med. 2022 Sep 30;12(10):1614. doi: 10.3390/jpm12101614.
4
The Role of KIT Mutations in Anaphylaxis.KIT 基因突变在过敏反应中的作用。
Curr Allergy Asthma Rep. 2019 Apr 26;19(6):31. doi: 10.1007/s11882-019-0863-5.
5
Exercise-induced anaphylaxis with an Ayurvedic drug as cofactor: A case report.以一种阿育吠陀药物作为辅助因素的运动诱发性过敏反应:一例报告。
World J Clin Cases. 2019 Mar 6;7(5):623-627. doi: 10.12998/wjcc.v7.i5.623.
6
A survey of anaphylaxis etiology and treatment.过敏反应的病因与治疗调查。
Med Gas Res. 2019 Jan 9;8(4):129-134. doi: 10.4103/2045-9912.248262. eCollection 2018 Oct-Dec.

本文引用的文献

1
Food-Dependent, Exercise-Induced Anaphylaxis: Diagnosis and Management in the Outpatient Setting.食物依赖运动诱发的过敏反应:门诊环境中的诊断与管理
J Allergy Clin Immunol Pract. 2017 Mar-Apr;5(2):283-288. doi: 10.1016/j.jaip.2016.11.022.
2
2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.循证医学基础的2015年更新:世界过敏组织过敏反应指南。
World Allergy Organ J. 2015 Oct 28;8(1):32. doi: 10.1186/s40413-015-0080-1. eCollection 2015.
3
Anaphylaxis in adolescents: a potential tripartite management framework.青少年过敏反应:一个潜在的三方管理框架。
Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):344-9. doi: 10.1097/ACI.0000000000000176.
4
H1-antihistamines for primary mast cell activation syndromes: a systematic review.抗组织胺 H1 治疗原发性肥大细胞活化综合征:系统评价。
Allergy. 2015 Sep;70(9):1052-61. doi: 10.1111/all.12672. Epub 2015 Jul 6.
5
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.过敏反应:欧洲过敏与临床免疫学会指南。
Allergy. 2014 Aug;69(8):1026-45. doi: 10.1111/all.12437. Epub 2014 Jun 9.
6
Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.奥马珠单抗治疗控制不佳的过敏性鼻炎:随机临床试验的系统评价和荟萃分析。
J Allergy Clin Immunol Pract. 2014 May-Jun;2(3):332-40.e1. doi: 10.1016/j.jaip.2014.02.001.
7
Idiopathic anaphylaxis.特发性过敏反应。
J Allergy Clin Immunol Pract. 2014 May-Jun;2(3):243-50; quiz 251. doi: 10.1016/j.jaip.2014.02.012. Epub 2014 Apr 6.
8
The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis.ISAAC 过敏原阵列在特发性过敏症研究中的应用。
Clin Exp Immunol. 2014 Aug;177(2):483-90. doi: 10.1111/cei.12334.
9
Idiopathic anaphylaxis.特发性过敏反应。
Allergy Asthma Proc. 2014 Jan-Feb;35(1):17-23. doi: 10.2500/aap.2014.35.3717.
10
Impact of caffeine on weight changes due to ketotifen administration.咖啡因对因服用酮替芬导致的体重变化的影响。
Adv Pharm Bull. 2014;4(1):83-9. doi: 10.5681/apb.2014.013. Epub 2013 Dec 23.

特发性过敏反应

Idiopathic Anaphylaxis.

作者信息

Nwaru Bright I, Dhami Sangeeta, Sheikh Aziz

机构信息

Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Medical School Doorway 3, Teviot Place, Edinburgh, EH8 9AG UK.

Evidence Based Healthcare Ltd, Edinburgh, UK.

出版信息

Curr Treat Options Allergy. 2017;4(3):312-319. doi: 10.1007/s40521-017-0136-2. Epub 2017 Jun 3.

DOI:10.1007/s40521-017-0136-2
PMID:28890861
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5569651/
Abstract

Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up investigating possible triggers and underlying predisposing factors. Key diagnostic tests include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in some cases for allergen challenge tests. Other recognized causes of anaphylaxis, such as foods, medications, insect stings, latex, and exercise, should all be considered, as should differential diagnoses such as asthma. While the cause of idiopathic anaphylaxis remains unknown, prompt treatment with intramuscular epinephrine (adrenaline) administered into the anterolateral aspect of the thigh is associated with good prognosis. There may also be a role for H1-antihistamines and corticosteroids as second-line agents. Patients need to be carefully monitored for signs of deterioration and/or a possible protracted or biphasic reaction. Patients with frequent episodes of anaphylaxis (e.g., six or more episodes/year) should be considered for preventive therapy, which may include corticosteroids, H1- and H2-antihistamines, and, in some cases, mast cell stabilizers such as ketotifen. Alternative immune-suppressants (e.g., methotrexate) and anti-IgE may rarely also need to be considered. In many cases, the frequency of anaphylaxis declines such that regular use of corticosteroids can be discontinued after 9-12 months. Pediatric patients should be treated with similar regimens as adults, but with appropriate dose adjustments. Patients should carry their self-injectable epinephrine and other emergency medications at all times in order to deal with emergency situations.

摘要

特发性过敏反应是一种罕见的危及生命的疾病,其症状与其他形式的过敏反应相似。目前缺乏强有力的证据基础来支持过敏反应的治疗,对于特发性过敏反应的证据更是少之又少。因此,大部分证据来自相对较小的病例系列和专家意见。特发性过敏反应是一种排除性诊断,需要详细的病史和仔细的诊断检查,以调查可能的触发因素和潜在的易感因素。关键的诊断测试包括皮肤点刺试验、特异性IgE检测、组分分辨诊断,在某些情况下还包括过敏原激发试验。还应考虑其他公认的过敏反应原因,如食物、药物、昆虫叮咬、乳胶和运动,以及哮喘等鉴别诊断。虽然特发性过敏反应的病因尚不清楚,但在大腿前外侧注射肌肉注射肾上腺素(肾上腺素)进行及时治疗与良好的预后相关。H1抗组胺药和皮质类固醇作为二线药物可能也有作用。需要密切监测患者是否有病情恶化和/或可能的迁延或双相反应的迹象。对于频繁发生过敏反应的患者(例如,每年发作6次或更多次),应考虑进行预防性治疗,可能包括皮质类固醇、H1和H2抗组胺药,在某些情况下还包括肥大细胞稳定剂,如酮替芬。也可能很少需要考虑使用其他免疫抑制剂(如甲氨蝶呤)和抗IgE。在许多情况下,过敏反应的频率会下降,以至于9至12个月后可以停止定期使用皮质类固醇。儿科患者应采用与成人相似的治疗方案,但需适当调整剂量。患者应随时携带自行注射的肾上腺素和其他急救药物,以应对紧急情况。